+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.

Age: 12Years - 80YearsAll GendersPhase 3
220 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
E

Actively Recruiting

This research aims to evaluate cryotherapy as a treatment for adults with chronic rhinitis who continue to have symptoms like a runny nose despite appropriate medical care. The study focuses on a new, minimally invasive method that freezes the nerves at the back of the nose using local anesthetic in an outpatient clinic. The goal is to explore how feasible this treatment is within the National Health Service outpatient setting before larger trials are planned. Participants will receive a single cryotherapy session targeting the posterior nasal nerves. This procedure is performed in the clinic under local anesthesia to reduce symptoms of persistent rhinitis. The study includes a small group of 5 to 10 patients who have rhinitis resistant to standard treatments. Alongside the treatment visit, participants will have a follow-up visit at 6 weeks and a usual 3-month follow-up visit. During the study, participants will complete questionnaires to report their symptoms and quality of life at these visits. Researchers will also record details like how long the procedure takes and how easy it is to perform. The main outcomes measured are changes in watery nasal discharge and various symptom and quality of life scores at 6 weeks and 3 months. The total study duration includes the treatment and follow-up visits, with careful monitoring of symptom changes.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.

Age: 45Years - 80YearsAll GendersPhase 3
57 locations
S

Actively Recruiting

This observational study focuses on patients with end stage kidney disease ESKD undergoing haemodialysis HD or haemodiafiltration HDF. It aims to understand differences in middle molecules clearance and patient outcomes between high 23 Litres and low <23 Litres convection volume HDF treatments. The study also evaluates how dialysate fluid sodium concentration 137 vs 140 mmolL affects overhydration volume in patients receiving HD and HDF. Participants are observed in groups based on their treatment type those receiving high or low convection volume HDF and those dialysing with different dialysate sodium concentrations 137 or 140 mmolL. No additional interventions are administered, as this study monitors routine dialysis treatments to assess toxin clearance, fluid status, and sodium balance in real-world settings. Participants will be monitored for 12 months to assess the effect of convection volume and dialysate sodium concentration on middle molecules clearance and patient-reported outcomes such as fatigue and recovery time. Long-term follow-up over 5 years will examine the relationship between middle molecule clearance and major cardiovascular events and hospitalizations. Data collection includes clinical evaluations, patient questionnaires, fluid status measurements, and biochemical markers to comprehensively assess dialysis adequacy and patient health.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are investigating the relationship between lipoproteina Lpa levels in the blood and the bodys natural ability to dissolve blood clots, called endogenous fibrinolysis. This study focuses on patients with atherosclerotic cardiovascular disease or aortic valve disease, aiming to understand if reducing Lpa with medications like PCSK9 inhibitors or inclisiran can improve clot dissolution and potentially lower the risk of heart attacks and strokes. Elevated Lpa is considered a risk factor that may impair fibrinolysis, and new cholesterol-lowering treatments have shown promise in reducing these levels. The study involves assessing patients who are eligible for treatment with PCSK9 inhibitors or inclisiran and those diagnosed with moderate or severe aortic valve calcification. Blood clotting and fibrinolysis will be measured using specialized tests such as the Global Thrombosis Test and thromboelastography. Lpa levels will be measured through immunoassays. Assessments will occur before starting treatment and again 3 to 6 months after treatment initiation for those receiving therapy. Patients with aortic valve calcification will be assessed once. During participation, blood samples will be collected to analyze clotting and fibrinolysis markers, as well as Lpa levels. The study will review thrombotic status and Lpa levels at 3 to 6 months to evaluate changes. This observational study involves monitoring without altering usual care. The total duration of involvement varies, depending on treatment eligibility and follow-up timing. The research is sponsored by the East and North Hertfordshire NHS Trust to better understand clotting risks and treatment responses in cardiovascular patients.

Age: 18Years +All Genders
1 location
U

Actively Recruiting

Researchers are studying patients with aortic valve disease who are undergoing either surgical aortic valve replacement SAVR or transcatheter aortic valve implantation TAVI to understand the risk of thrombosis and related complications. This observational study aims to use novel blood biomarkers to assess clotting and clot breakdown, identifying patients at risk for valve thrombosis and related adverse events such as stroke, systemic embolism, and valve failure. The study also seeks to determine the time periods when the risk of valve thrombosis is highest. Participants will have blood tests at several time points to measure thrombosis and thrombolysis markers, which may be influenced by their prescribed blood-thinning medications. They will be monitored using 4D CT scans, echocardiography, and clinical reviews to detect adverse events including major cardiac and cerebrovascular events, valve thrombosis, bleeding, and new or worsening atrial fibrillation. These evaluations will continue regularly over a five-year follow-up period. Throughout the study, participants will provide blood samples and undergo imaging and clinical assessments to track their health and valve function. Researchers will closely observe clinical outcomes such as major cardiac events, strokes, systemic embolism, and bleeding over the five years. This long-term monitoring helps identify when patients face the greatest risks and how well blood tests predict these complications, supporting safer, targeted treatment approaches.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
F

Actively Recruiting

This research aims to understand factors that influence serum bicarbonate levels in patients undergoing maintenance dialysis, focusing on those with metabolic acidosis and chronic kidney disease CKD on hemodialysis. The study is observational and conducted at a single center to explore how different dialysis methods affect bicarbonate control and to consider personalizing dialysate concentrations for individual patients. Participants will not receive any experimental treatment but will be observed while on their regular dialysis schedule, which occurs three times per week. Researchers will collect demographic data, medical and dialysis histories, and dietary information through food diaries over two days. Bicarbonate levels will be measured at three different times before and after one dialysis session and before the next session. Throughout the study, participants will provide data through routine dialysis sessions and recorded diet. The study will assess changes in serum bicarbonate over three months, dietary acid load, the volume of hemodiafiltration, and dialysis dose indicators. This will help evaluate how well dialysis manages bicarbonate levels and explore individualized dialysis approaches. Participation duration aligns with the three-month observation period.

Age: 18Years +All Genders
1 location

1-10 of 22

1